Blog
RSS FeedPosted by Michael Wonder on 14 Jan 2022
PBAC Public Summary Documents – September 2021 meeting (first time rejections and deferrals)
14 January 2022 - The Public Summary Documents (first time rejections and deferrals) from the September 2021 PBAC meeting are now ...
Posted by Michael Wonder on 06 Jan 2022
ICER publishes evidence report on tirzepatide for type 2 diabetes
6 January 2022 - Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as ...
Posted by Michael Wonder on 26 Dec 2021
Public Summary Documents – September 2021 PBAC meeting
24 December 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the September 2021 PBAC ...
Posted by Michael Wonder on 26 Dec 2021
PBS expenditure and prescriptions report 2020-21
24 December 2021 - The PBS Expenditure and Prescriptions Report 1 July 2020 to 30 June 2021 is now available. ...
Posted by Michael Wonder on 26 Dec 2021
Report on the collection of under co-payment data 2020-21
24 December 2021 - The report on the collection of under co-payment data 2020-21 is now available. ...
Posted by Michael Wonder on 02 Dec 2021
Call for a central portal for clinical study reports
1 December 2021 - In an open-access publication in the Journal of European CME, two authors from IQWiG argue that ...
Posted by Michael Wonder on 25 Nov 2021
Preparing for health care’s new frontier: Committee releases major report on reforming the process for new medicines and health technology
25 November 2021 - A new parliamentary report ‘The New Frontier: Delivering better health for all Australians’ is recommending significant ...
Posted by Michael Wonder on 25 Nov 2021
MTAA welcomes new frontiers report
25 November 2021 - The Medical Technology Association of Australia wishes to thank Trent Zimmerman MP and Dr Mike Freelander MP ...
Posted by Michael Wonder on 24 Nov 2021
Semaglutide (Wegovy) stakeholder meeting outcome statement
24 November 2021 - The outcome statement for the semaglutide stakeholder meeting held on 26 August 2021 is now available. ...
Posted by Michael Wonder on 17 Nov 2021
ICER publishes final evidence report and policy recommendations on mavacamten for hypertrophic cardiomyopathy
16 November 2021 - Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently ...
Posted by Michael Wonder on 13 Nov 2021
Public Summary Documents (first time rejections and deferrals) – July 2021 PBAC meeting
12 November 2021 - The Public Summary Documents (first time rejections and deferrals) from the July 2021 PBAC meeting are now ...
Posted by Michael Wonder on 09 Nov 2021
ICER releases draft evidence report on tirzepatide for type 2 diabetes mellitus
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 05 Nov 2021
Drug Utilisation Sub-Committee outcome statement
5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available. ...
Posted by Michael Wonder on 04 Nov 2021
ICER publishes evidence report on tezepelumab for severe asthma
4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic ...
Posted by Michael Wonder on 20 Oct 2021
ICER publishes final evidence report and policy recommendations on therapies for myasthenia gravis
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...